Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals

Big Pharma faces a ~$300B “patent cliff” as major drugmakers accelerate spending (at the fastest pace since 2019) to replace medicines losing patent protection. While the pressure is a headwind for legacy portfolios, the article frames biotech with promising late-stage drugs as the likely beneficiaries. Overall, the news is mildly positive for drug developers poised to capture post-patent demand.

Analysis

Big Pharma faces a ~$300B “patent cliff” as major drugmakers accelerate spending (at the fastest pace since 2019) to replace medicines losing patent protection. While the pressure is a headwind for legacy portfolios, the article frames biotech with promising late-stage drugs as the likely beneficiaries. Overall, the news is mildly positive for drug developers poised to capture post-patent demand.